{"schema_version":"secwatch.filing_event.v1","accession":"0001689548-24-000035","form_type":"8-K","ticker":"PRAX","cik":"0001689548","company_name":"Praxis Precision Medicines, Inc.","filed_at":"2024-03-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.123208+00:00","generated_at":"2026-06-05T03:50:56.447438+00:00","sec_items":["2.02","7.01","8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Praxis: FY2023 net loss $123.3M; cash $247.6M; ulixacaltamide Phase 3 on track, PRAX-628 topline expected 1Q24","bullets":["Cash and equivalents $247.6M as of Feb 29, 2024, funded by $161.7M January 2024 follow-on; runway into 2026.","FY2023 net loss $123.3M vs $214.0M in 2022; R&D expenses fell to $86.8M from $155.0M.","Essential3 Phase 3 program for ulixacaltamide (ET) has >3,000 pre-qualified referrals; enrollment due 1H24, topline 2H24.","PRAX-628 PPR study 15 mg cohort exceeded expectations; topline data expected Q1 2024; Phase 2b plan in 2H24.","Elsunersen (PRAX-222): 43% median seizure reduction in EMBRAVE Part 1; EMA PRIME designation for SCN2A DEE."],"urls":{"canonical":"https://secwatch.observer/filing/0001689548-24-000035","json":"https://secwatch.observer/filing/0001689548-24-000035.json","markdown":"https://secwatch.observer/filing/0001689548-24-000035.md","text":"https://secwatch.observer/filing/0001689548-24-000035.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1689548/000168954824000035/0001689548-24-000035-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1689548/000168954824000035/prax-20240305.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T03:50:56.447438+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5a45a0b8e501ed15eea0f67f256ea5e6299a3632","claim":"Praxis Precision Medicines, Inc. reported financial results for fourth quarter and full-year 2023.","evidence_excerpt":"On March 5, 2024, Praxis Precision Medicines, Inc. (the “Company”) announced its financial results for the quarter and full year ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1689548/000168954824000035/0001689548-24-000035-index.htm","confidence":0.85,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter and full-year 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}